Default company panoramic image
D624f333 5a10 4010 860a ca8971f52357

Integene International LLC

Platform technology unique patented gene therapy treatments for peripheral artery disease (CLI) , ischemic heart disease .

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Miami, FL, USA
  • Currency USD
  • Founded June 2010
  • Employees 2
  • Website

Company Summary

Biotech. Unique platform technology for treatments of vascular diseases. Engineered Gene Therapy and Stem Cell Therapy creates directional angiogenesis. Very strong preclinical data. Peripheral Artery Disease (PAD). T2 diabetes epidemic causes critical lower limb ischemia (CLI) 200,000 gangrenous amputations in US. annually. GenstemX Therapy potential cure. 60% of all patients with T2 globally will get this disease. NO pharmacological cure.


  • Default avatar
    Michael M. Gold
    Executive Chairman

    Co -founder and investor.40 years experience in corporate development. Mr Gold was a founder of Triad Bank NC. Founder of Vectrix Corporation the worlds first low cost computer graphics system, and has had a successful career in real estate development and mangement.

  • Default avatar
    Ken Andrews
    Acting CEO

    Mr Andrews has more than 30 years of experience in the health care field. He was Director of Sales for Genentech of CA. Senior VP for Seikagaku Corp. of Japan. VP marketing and sales Genzyme and served as CEO of Medicalis of Boston. Most recently has served as CEO of Histogenics MA, raising more than $20MM in funding.

  • Default avatar
    Dr. Keith Wesbter.Ph.D., FAHA
    President. Director of R&D

    Dr Webster is a Professor at the University Of Miami Miller School. Director of the Vascular Biology Institute. He holds the Walter G. Ross Distinguished Chair of Vascular Biology. He has published more than 150 papers in his field.


  • Default avatar
    Stewart Merkin. P.A.
    Default avatar
    Cherry Bekaert LLP

Previous Investors

  • Default avatar
    Michael Gold.